There is much interest in combination approaches that target epigenetic readers/writers/erasers, and in the current investigation, deacetylase plus bromodomain inhibition prioritized ERCC2 (Figure 2), with potential prognostic relevance for CRC patients (Figure 3). This evidence concerns the gene ERCC2 and colorectal carcinoma.